Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Delgocitinib Ointment in Japanese Pediatric Patients with Atopic Dermatitis
jRCT2080224005Phase 3Completed
- Sponsor
- Japan Tobacco
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of delgocitinib in atopic dermatitis (AD) (3 arms), sponsored by Japan Tobacco. Primary endpoint: Percent improvement in modified Eczema Area and Severity Index (mEASI) at end of treatment (EOT) at Week 4. Started Aug 2018; status: completed.
02
Drugs
delgocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2080224005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224005.